Page last updated: 2024-12-08
tops
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
TOPS: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23679008 |
| SCHEMBL ID | 5525901 |
| MeSH ID | M0064879 |
Synonyms (29)
| Synonym |
|---|
| c12h18nnao3s |
| tops |
| 3-(n-ethyl-3-methylanilino)propanesulfonic acid sodium salt |
| FT-0639652 |
| 40567-80-4 |
| sodium 3-(n-ethyl-3-methylanilino)propanesulfonate |
| AKOS016004622 |
| 3-(ethyl[3-methylphenyl]amino)-1-propanesulfonic acid |
| n-ethyl-n-sulfopropyl-m-toluidine sodium salt |
| sodium n-ethyl-n-(3-sulfopropyl)-m-toluidine |
| n-ethyl-n-(3-sulfopropyl)-3-methylaniline sodium salt |
| AKOS015897332 |
| HY-15933 |
| SCHEMBL5525901 |
| n-ethyl-n-(3-sulfopropyl)-3-methylaniline,sodium salt (tops) |
| n-ethyl-n-sulphopropyl-m-toluidine, sodium salt |
| n-ethyl-n-sulfopropyl-3-toluidine sodium salt |
| tops, sodium salt |
| n-ethyl-n-(3-sulfopropyl)-3-methylaniline, sodium salt |
| W-202667 |
| sodium 3-(ethyl(m-tolyl)amino)propane-1-sulfonate |
| AC-27729 |
| mfcd00043050 |
| sodium 3-[ethyl(m-tolyl)amino]propane-1-sulfonate |
| n-ethyl-n-(3-sulfopropyl)-3-methylaniline,sodiumsalt (tops) |
| SY047636 |
| 4-amino-6-cyano-3(2h)-quinazolinecarboxylicacid-1,1-dimethylethylester |
| AC7889 |
| sodium;3-(n-ethyl-3-methylanilino)propane-1-sulfonate |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The acute LD50 doses in rats for PCA and TES are 15." | ( Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis. Afzal, V; Brasch, RC; Nitecki, DE; Wolff, S, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (75.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (17.65%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 2 (11.76%) | 0.25% |
| Other | 12 (70.59%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||